Division of Agilent Technologies Inc.
Latest From Dako Corp.
Top-line data from KEYNOTE-010 suggest opportunity for Keytruda to broaden its reach to a wider population with lower expression of the PD-L1 biomarker.
The latest drug development news and highlights from our FDA Performance Tracker.
With approval of Merck’s PD-1 inhibitor Keytruda and PD-L1 companion diagnostic in the valuable lung cancer indication, Wall Street’s attention starts turning toward reimbursement and commercialization.
Though Merck’s Keytruda was recently approved for the full range of lung cancer patients, giving it a marketable advantage over the limited approval for Bristol's Opdivo in squamous disease, Bristol has caught up again with early FDA approval for the non-squamous population. FDA also added PD-L1 expression data to Opdivo’s label.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Agilent Technologies Inc.
- Senior Management
- Viggo Harboe, CEO
- Contact Info
Phone: (805) 566-6655
6392 Via Real
Carpinteria, CA 93013
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.